Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00565539 · ClinicalTrials.gov registry record · Phase 1

Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection

A Phase 1 study of Hepatitis C, Chronic, sponsored by ZymoGenetics.

Completed
Registry status
Phase 1
Development phase
56
Enrollment target
11
Study locations

NCT00565539 is a Phase 1 study of Hepatitis C, Chronic that has completed, run by ZymoGenetics. The registered enrollment target is 56 participants, below the 374-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (85% lower). The trial reports 11 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00565539, a Phase 1 study of Hepatitis C, Chronic, has completed, sponsored by ZymoGenetics.

COMPLETED
Registry status
Phase 1
Development phase
56 participants
Enrollment target
11
Study locations

Study Summary

Interleukin 29 (IL-29) is a substance that is produced in the body to help fight viral infections. The purpose of this study is to test the safety and antiviral effects of PEG-rIL-29 (a man-made form of IL-29) when it is given either by itself at different doses or in combination with the approved dose of ribavirin (an antiviral drug) to subjects with hepatitis C infection who have received no prior treatment for this disease or who have relapsed following previous treatment with PEGylated interferon alpha (PEG-IFN-α), or other form of IFN-α, and ribavirin.

Conditions Studied

Hepatitis C, Chronic

Interventions

  • DRUG PEGylated recombinant interleukin 29 (PEG-rIL-29)

Study Locations (11)

Texas

  • Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine - Houston
  • St. Luke's Advanced Liver Therapies - Houston
  • Alamo Medical Research - San Antonio

Illinois

  • Northwestern Memorial Hospital - Chicago

Michigan

  • Henry Ford Health System - Detroit

Minnesota

  • Mayo Clinic - Rochester

New Jersey

  • University Hospital (UMDNJ) - Newark

North Carolina

  • Duke University Medical Center - Durham

Oregon

  • Oregon Health Sciences University - Portland

Virginia

  • VCUHS Hepatology Research Division - Richmond

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2007-12
Est. Completion 2009-10
Phase Phase 1

Sponsor

ZymoGenetics

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00565539

The ClinicalTrials.gov registry entry for NCT00565539 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (85% lower). The listed sponsor is ZymoGenetics, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis C, Chronic appearing as the primary indexed condition, and to 1 intervention - of which PEGylated recombinant interleukin 29 (PEG-rIL-29) is the first listed.

NCT00565539 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Texas, Illinois, Michigan.

Frequently Asked Questions

What is clinical trial NCT00565539 about?

NCT00565539 is a clinical study titled "Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection". Interleukin 29 (IL-29) is a substance that is produced in the body to help fight viral infections. The purpose of this study is to test the safety and antiviral effects of PEG-rIL-29 (a man-made form of IL-29) when it is given either by itself at different doses or in combination with the approved d...

What is the current status of trial NCT00565539?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2007-12. Estimated completion is 2009-10.

What conditions does trial NCT00565539 study?

This clinical trial studies the following conditions: Hepatitis C, Chronic.

What interventions are being tested in trial NCT00565539?

The interventions under investigation include: PEGylated recombinant interleukin 29 (PEG-rIL-29) (DRUG).

Who is sponsoring clinical trial NCT00565539?

This trial is sponsored by ZymoGenetics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00565539 being conducted?

This trial has 11 study locations across Illinois, Michigan, Minnesota, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C, Chronic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C, Chronic

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.